SLLN-15

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

SLLN-15（自噬诱导剂 SLLN-15）是一种有效的口服自噬诱导剂，可在 TNBC 临床前模型中选择性激活细胞抑制性巨自噬/自噬。

SLLN-15 (Autophagy inducer SLLN-15) is a potent, orally available inducer of autophagy that selectively activated cytostatic macroautophagy/autophagy in TNBC preclinical models, promotes AURKA degradation and ; induced a dose-dependent anti-proliferative activity in the TNBC cell lines MDA-MB-231 and BT-20 via induction of autophagy and autophagic flux, associated with a selective inhibition of AKT-MTOR signaling; SLLN-15-induced autophagy in TNBC cells was also associated with decreased AURKA expression decreased AKT phosphorylation and subsequent blockage of the AKT-MTOR pathway; demonstrates anticancer and anti-metastatic activity in mice bearing TNBC.

——

——

Autophagy inducer SLLN-15

Autophagy

Autophagy

Autophagy

——

——

——

507.362

C19H23N7Se2

>98% (HPLC)

——

C12=NC(NC3=CC=C(N4CC[Se]CC4)C=C3)=NC(N[C@@H]5C[Se]CC5)=C1N=CN2

(S)-N2-(4-selenomorpholinophenyl)-N6-(tetrahydroselenophen-3-yl)-9H-purine-2,6-diamine

(-20℃)

With Ice Pack

≥ 2 years